Complement Therapeutics Receives FDA Fast Track Designation for CTx001 for Geographic Atrophy Secondary to AMD

jones
c4fa47dcdec6988f332e51d00d0c0500 Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD
  • The FDA has granted Fast Track designation to CTx001 for treating Geographic Atrophy secondary to Age-related Macular Degeneration
  • CTx001 is an experimental AAV-based gene therapy that aims to regulate several pathways in the complement system
  • CTx001 previously obtained FDA IND clearance and will be assessed in Opti-GAIN, a first-in-human Phase I/II clinical study

MUNICH, Jan. 8, 2026 — Complement Therapeutics GmbH (CTx), a clinical-stage biotech firm focused on developing advanced treatments for complement-driven disorders, announced today that the U.S. Food and Drug Administration (FDA) has awarded Fast Track Designation to CTx001, its primary gene therapy candidate for Geographic Atrophy (GA) associated with Age-related Macular Degeneration (AMD). The FDA had previously approved the Investigational New Drug (IND) application for CTx001, allowing the programme to move forward into clinical development.

Complement Therapeutics Logo

The Fast Track designation aims to streamline the development and accelerate the review of medications for serious conditions that could fulfill unmet medical needs. This program enables more regular communication with the FDA and helps deliver crucial new treatments to patients faster.

CTx001 is an innovative adeno-associated virus (AAV) gene therapy created to deliver a shortened form of Complement Receptor 1 (mini-CR1), offering the possibility of sustained, powerful regulation of both classical and alternative complement cascade pathways. GA represents an advanced stage of dry AMD causing permanent vision impairment, and currently has few treatment options.

“Receiving FDA Fast Track Designation for CTx001 marks a significant regulatory milestone, recognising the severity of Geographic Atrophy, the unmet medical needs of patients, and the innovative promise of CTx001 to effectively meet those needs,” stated Dr. Rafiq Hasan, Chief Executive Officer of Complement Therapeutics. “Combined with the recent IND clearance, this designation bolsters our initiative to swiftly progress CTx001 into clinical development as we strive to combat a major cause of permanent vision loss.”

CTx001 will be tested in the Opti-GAIN (Optimised Geographic Atrophy Interventional) first-in-human Phase I/II clinical study involving patients with Geographic Atrophy secondary to AMD. The first patient dosing is anticipated in the U.S. during the first quarter of 2026.

For more information visit

Logo –

SOURCE Complement Therapeutics

jones